Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × tanespimycin × Clear all

Phase

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Lung Neoplasms 2 Hematologic Neoplasms 2 Gastrointestinal Stromal Tumors 2 Advanced Malignancies 2 Solid Tumor 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Melanoma 1 Liposarcoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Diseases 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1

Interventions

Prednisone 92 Docetaxel 66 enzalutamide 64 Abiraterone Acetate 62 Leuprolide 45 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 41 abiraterone 29 apalutamide 26 bicalutamide 23 Prednisolone 23 pembrolizumab 20 Zoledronic Acid 20 Goserelin 20 radium Ra 223 dichloride 19 darolutamide 19 cabazitaxel 15 Triptorelin Pamoate 14 sipuleucel-T 12 luprolide acetate gel depot 12 Androgen Antagonists 12 Dexamethasone 11 olaparib 10 Injections 10 gallium 68 PSMA-11 9 Pluvicto 9 Mitoxantrone 9 Ipilimumab 9 Cyclophosphamide 8 relugolix 7 orteronel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00564928 2012-12-11

IPI-504-04

Infinity Pharmaceuticals, Inc.

Phase 2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡